Thymosin Alpha-1

Key points

• Thymosin alpha-1 is a 28 amino acid peptide modelled on a natural product of the thymus gland.
• It is thought to fine tune the immune response rather than simply boost or suppress it.
• It is a licensed medicine in around 35 countries (sold as Zadaxin), mainly for hepatitis B and C and as a support in some cancer care. It is not licensed in the UK.
• The firmest evidence is in chronic hepatitis B; use for general immune support is far less established.

Quick facts

What it is

Immune modulating peptide, 28 amino acids

Approved use

Hepatitis B and C; cancer care support (some countries)

UK status

Not a licensed medicine; no UK marketing authorisation

Human evidence

Strongest in chronic hepatitis B

How it works

Thymosin alpha-1 acts on Toll like receptors, the immune system's early warning sensors, and supports the development and activity of T cells, the white blood cells that coordinate the response to infection. In cancer research it appears to shift certain immune cells away from a suppressive state towards a more active one. The overall idea is that it recalibrates immunity rather than forcing it in one direction.

What the evidence shows

The strongest human evidence is in chronic hepatitis B, with older work in hepatitis C that has largely been overtaken by newer antivirals. In cancer it has mostly been studied as an add on, with earlier stage evidence. Its use for general immune support, ageing or longevity is mostly preclinical or early, without the controlled trials in healthy people that would settle the question.

What it does not settle

• There is little controlled evidence for general immune optimisation in healthy people.
• Long term safety outside its licensed uses is not well established.
• Its effect in autoimmune conditions, where immune activation could matter, is poorly studied.

Side effects

Common

• It is generally described as well tolerated, especially next to the interferon therapies it was studied alongside.
• The most common reports are redness, tenderness or swelling at the injection site, and short lived tiredness.

Less common but serious

• In theory, broadly activating the immune system could affect an autoimmune condition, though this is not well studied.
• Where there is no UK licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

Thymosin alpha-1 has no UK marketing authorisation, so it is not a licensed medicine here. Its licensed use in other countries is a prescribed treatment given under medical supervision. Products sold online for other purposes are unlicensed and not quality assured.

Common questions